BOSTON, Mass., June 20, 2026
Velico Medical has announced successful results from its Phase 1 first-in-human clinical trial evaluating FrontlineODP™, a next-generation spray-dried plasma product designed to improve access to lifesaving plasma transfusions in emergency, military, disaster-response, and resource-limited healthcare settings. The multicenter, randomized, dose-escalation study, recently published in the journal Transfusion, demonstrated that FrontlineODP™ exhibited a safety profile comparable to standard frozen plasma (PF24) while offering significant operational advantages through its innovative spray-drying technology. The findings represent a major advancement in transfusion medicine and support the development of decentralized blood product solutions capable of overcoming longstanding logistical challenges associated with plasma storage and transportation. The announcement coincides with the installation of Velico’s FrontlineODP™ system at the South Texas Blood and Tissue Center, making it the first civilian blood center in the United States to adopt the technology.
Clinical Trial Demonstrates Safety and Feasibility
The Phase 1 clinical study enrolled 24 healthy volunteers across three sequential dose-escalation cohorts to evaluate the safety and tolerability of FrontlineODP™. Participants received escalating plasma doses up to 800 mL, including a randomized, double-blind crossover comparison with conventional frozen plasma products. Researchers reported that all participants successfully completed the study and that plasma infusions were well tolerated across all dosing levels. Importantly, investigators observed no thromboembolic events, while treatment-emergent adverse events occurred at frequencies similar to those seen with standard frozen plasma.
Minor coagulation changes detected during the trial were not considered clinically significant. The study also confirmed successful preservation of critical plasma proteins throughout the spray-drying manufacturing process. These findings provide strong evidence supporting the safety and biological integrity of FrontlineODP™ and establish an important foundation for future clinical development and regulatory review activities.
Decentralized Plasma Technology Addresses Critical Healthcare Challenges
Advertisement
Plasma transfusions play a vital role in the treatment of patients experiencing severe bleeding, traumatic injuries, and hemorrhagic shock, particularly when administered rapidly during emergency care. However, traditional plasma products require extensive cold-chain storage, freezing infrastructure, and lengthy thawing procedures, limiting availability in remote, prehospital, military, and disaster-response environments. Velico’s proprietary spray-dried plasma technology has been developed specifically to overcome these barriers.
FrontlineODP™ offers several operational advantages, including rapid reconstitution, lightweight packaging, elimination of frozen storage requirements, increased portability, and decentralized production capabilities. By enabling plasma to be stored and deployed without dependence on conventional cold-chain systems, the technology has the potential to significantly expand access to critical blood products in situations where traditional plasma is unavailable or difficult to deliver. Experts believe this innovation could transform emergency transfusion practices and improve survival outcomes for patients requiring urgent plasma support.
Supporting Military, Civilian, and Disaster Response Preparedness
The successful trial results highlight the growing importance of decentralized medical technologies capable of strengthening healthcare resilience during emergencies and large-scale crises. Velico’s FrontlineODP™ platform, along with its veliPod™ decentralized production system, is being evaluated for applications across military medicine, civilian trauma systems, disaster preparedness programs, and national blood resilience initiatives. The technology is designed to support localized plasma production and deployment strategies, helping healthcare organizations maintain critical transfusion capabilities even in challenging operational environments. With increasing global focus on emergency preparedness and healthcare infrastructure resilience, decentralized blood product solutions are gaining attention from governments, military organizations, and healthcare providers worldwide.
The publication of positive first-in-human clinical data represents a significant milestone for Velico and the broader transfusion medicine community. If future studies continue to demonstrate safety and effectiveness, FrontlineODP™ could play a transformative role in expanding plasma access, improving trauma care, and strengthening emergency medical response capabilities across both civilian and military healthcare systems.
Source: Velico Medical press release
